ArticleCancer medicine2021

A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy.

Xuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.